Raymond James downgraded Tvardi Therapeutics (TVRD) to Market Perform from Outperform without a price target The firm believes many open questions remain regarding TTI-101 following the unsuccessful REVERT-IPF readout. The discontinuation rate seen in the readout adds risk to this program, the analyst tells investors in a research note. Raymond James downgraded Tvardi to reflect the removal of the idiopathic pulmonary fibrosis opportunity and uncertainty on the path forward.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVRD:
- Tvardi Therapeutics Faces Setback in Phase 2 Trial
- Optimistic Buy Rating for Tvardi Therapeutics: Promising Potential of TTI-109 Amidst TTI-101 Setbacks
- Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Cantor downgrades Tvardi Therapeutics, sees ‘no path forward in IPF’